Literature DB >> 22614960

Preoperative evaluation of the lung resection candidate.

Peter Mazzone1.   

Abstract

Lung resection provides the greatest likelihood of cure for patients with localized lung cancer, but is associated with a risk of mortality, decreased postoperative lung function, and other complications. Lung function testing using spirometry, diffusing capacity of the lung for carbon monoxide, and peak oxygen consumption helps predict the risk of postoperative complications including mortality. Predicting postoperative lung function using the proportion of lung segments to be resected, radionuclide scanning, or other methods is important for assessing surgical risk. The American College of Chest Physicians, the European Respiratory Society/European Society of Thoracic Surgeons and the British Thoracic Society guidelines provide detailed algorithms for preoperative risk assessment, but their recommended approaches differ somewhat. Smoking cessation and pulmonary rehabilitation are perioperative measures that can improve patients' the short- and long-term outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22614960     DOI: 10.3949/ccjm.79.s2.04

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  14 in total

Review 1.  Surgical treatment of non-small-cell lung cancer in octogenarians.

Authors:  Miguel Guerra; Paulo Neves; José Miranda
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-08

2.  Importance of Smoking Cessation in a Lung Cancer Screening Program.

Authors:  Vidit Munshi; Pamela McMahon
Journal:  Curr Surg Rep       Date:  2013-12

3.  Computed tomography-guided microwave ablation for non-small cell lung cancer patients on antithrombotic therapy: a retrospective cohort study.

Authors:  Sheng Xu; Zhi-Xin Bie; Yuan-Ming Li; Bin Li; Jin-Zhao Peng; Fan-Lei Kong; Xiao-Guang Li
Journal:  Quant Imaging Med Surg       Date:  2022-06

4.  Efficacy of Lung-Tuned Monopole Antenna for Microwave Ablation: Analytical Solution and Validation in a Ventilator-Controlled ex Vivo Porcine Lung Model.

Authors:  Jason Chiang; Lingnan Song; Fereidoun Abtin; Yahya Rahmat-Samii
Journal:  IEEE J Electromagn RF Microw Med Biol       Date:  2021-03-17

Review 5.  Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors.

Authors:  Arian Mansur; Tushar Garg; Apurva Shrigiriwar; Vahid Etezadi; Christos Georgiades; Peiman Habibollahi; Timothy C Huber; Juan C Camacho; Sherif G Nour; Alan Alper Sag; John David Prologo; Nariman Nezami
Journal:  Diagnostics (Basel)       Date:  2022-05-24

Review 6.  Surgery in 2013 and beyond.

Authors:  Rishendran Naidoo; Morgan N Windsor; Peter Goldstraw
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 7.  Surgical strategies in the therapy of non-small cell lung cancer.

Authors:  Feras Al-Shahrabani; Daniel Vallböhmer; Sebastian Angenendt; Wolfram T Knoefel
Journal:  World J Clin Oncol       Date:  2014-10-10

8.  CT Densitometry and Morphology of Radiofrequency-Ablated Stage IA Non-Small Cell Lung Cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) Trial.

Authors:  Erica S Alexander; Lillian Xiong; Grayson L Baird; Hiran Fernando; Damian E Dupuy
Journal:  J Vasc Interv Radiol       Date:  2020-01-03       Impact factor: 3.464

9.  Tissue spray ionization mass spectrometry for rapid recognition of human lung squamous cell carcinoma.

Authors:  Yiping Wei; Liru Chen; Wei Zhou; Konstantin Chingin; Yongzhong Ouyang; Tenggao Zhu; Hua Wen; Jianhua Ding; Jianjun Xu; Huanwen Chen
Journal:  Sci Rep       Date:  2015-05-11       Impact factor: 4.379

10.  Influence of patient's physiologic factors and immobilization choice with stereotactic body radiotherapy for upper lung tumors.

Authors:  Terence T Sio; Andrew R Jensen; Robert C Miller; Luis E Fong de los Santos; Christopher L Hallemeier; Nathan R Foster; Sean S Park; Heather J Bauer; Kenneth Chang; Yolanda I Garces; Kenneth R Olivier
Journal:  J Appl Clin Med Phys       Date:  2014-09-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.